Annovis Bio Stock EBITDA
| ANVS Stock | USD 6.56 0.51 7.21% |
Annovis Bio fundamentals help investors to digest information that contributes to Annovis Bio's financial success or failures. It also enables traders to predict the movement of Annovis Stock. The fundamental analysis module provides a way to measure Annovis Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Annovis Bio stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -45 M | -42.8 M |
Annovis | EBITDA |
Annovis Bio Company EBITDA Analysis
Annovis Bio's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Annovis Bio EBITDA | (45.04 M) |
Most of Annovis Bio's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Annovis Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Annovis EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Annovis Bio is extremely important. It helps to project a fair market value of Annovis Stock properly, considering its historical fundamentals such as EBITDA. Since Annovis Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Annovis Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Annovis Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Annovis Ebitda
Ebitda |
|
According to the company disclosure, Annovis Bio reported earnings before interest,tax, depreciation and amortization of (45.04 Million). This is 105.13% lower than that of the Biotechnology sector and 144.96% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.16% higher than that of the company.
Annovis EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Annovis Bio's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Annovis Bio could also be used in its relative valuation, which is a method of valuing Annovis Bio by comparing valuation metrics of similar companies.Annovis Bio is currently under evaluation in ebitda category among its peers.
Annovis Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Annovis Bio from analyzing Annovis Bio's financial statements. These drivers represent accounts that assess Annovis Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Annovis Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 43.2M | 47.6M | 134.1M | 109.6M | 98.7M | 55.8M | |
| Enterprise Value | 43.6M | 39.5M | 88.4M | 81.2M | 73.1M | 44.9M |
Annovis Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Annovis Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Annovis Bio's managers, analysts, and investors.Environmental | Governance | Social |
Annovis Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Annovis Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Annovis Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Annovis Bio's value.| Shares | Bridgeway Capital Management, Llc | 2024-09-30 | 22.1 K | Northern Trust Corp | 2024-09-30 | 21.9 K | Spears Abacus Advisors Llc | 2024-09-30 | 20 K | Bank Of New York Mellon Corp | 2024-06-30 | 19.1 K | Greenwich Wealth Management Llc | 2024-09-30 | 16.5 K | Ubs Group Ag | 2024-06-30 | 13 K | Lokken Investment Group Llc | 2024-06-30 | 12.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 11 K | Jane Street Group Llc | 2024-06-30 | 10.1 K | Vanguard Group Inc | 2024-09-30 | 380.3 K | Citadel Advisors Llc | 2024-09-30 | 102.7 K |
Annovis Fundamentals
| Return On Equity | -5.97 | ||||
| Return On Asset | -1.55 | ||||
| Current Valuation | 77.87 M | ||||
| Shares Outstanding | 13.8 M | ||||
| Shares Owned By Insiders | 20.40 % | ||||
| Shares Owned By Institutions | 8.83 % | ||||
| Number Of Shares Shorted | 1.39 M | ||||
| Price To Earning | (0.43) X | ||||
| Price To Book | 12.81 X | ||||
| EBITDA | (45.04 M) | ||||
| Net Income | (56.2 M) | ||||
| Cash And Equivalents | 35.97 M | ||||
| Cash Per Share | 4.41 X | ||||
| Total Debt | 17.96 M | ||||
| Debt To Equity | (0.31) % | ||||
| Current Ratio | 28.11 X | ||||
| Book Value Per Share | 0.53 X | ||||
| Cash Flow From Operations | (39.97 M) | ||||
| Short Ratio | 4.02 X | ||||
| Earnings Per Share | (4.22) X | ||||
| Target Price | 34.8 | ||||
| Beta | 1.7 | ||||
| Market Capitalization | 90.51 M | ||||
| Total Asset | 10.21 M | ||||
| Retained Earnings | (110.26 M) | ||||
| Working Capital | 5.93 M | ||||
| Current Asset | 986 K | ||||
| Current Liabilities | 216 K | ||||
| Net Asset | 10.21 M |
About Annovis Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Annovis Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annovis Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annovis Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.